Martin Treder — Chief Scientific Officer at Affimed N.V.

Dr. Martin Treder has been the Chief Scientific Officer of Affimed N.V. since January 1, 2015 and served as its Member of Management Board. Dr. Treder has 13 years of professional experience in the field of biotherapeutics research and development. Dr. Treder Co-Founded CT Atlantic Ltd. and served as its Chief Scientific Officer from 2011 to 2014, where he was responsible for establishing a broad research pipeline of various preclinical and clinical development programs. Dr. Treder had Senior positions at Neurimmune Therapeutics AG. Prior to CT Atlantic, Dr. Treder served as Program Director at U3 Pharma AG, a German biotech company developing targeted cancer therapeutics, where he headed the company's portfolio of innovative anti-HER3 therapeutic antibodies. Dr. Treder graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the University of W???rzburg, Germany. He earned his PhD working in Prof. Axel Ullrich's group at the Max Planck Institute of Biochemistry in Martinsried-Munich.